Sensitive detection of carcinoembryonic antigen using surface plasmon resonance biosensor with gold nanoparticles signal amplification
Sensitive detection of carcinoembryonic antigen using surface plasmon resonance biosensor with gold nanoparticles signal amplification
复制标题
DOI：
10.1016/j.talanta.2015.03.041
复制
发表时间：
2015-08-01
期刊：
影响因子：
6.1
通讯作者：
Zhou, Gao
中科院分区：
文献类型：
--
作者：
Li, Rong;Feng, Feng;Zhou, Gao
建立了一种利用表面等离子体共振（SPR）生物传感器实时检测人血清中癌胚抗原（CEA）的新方法。两种抗体均能识别不同抗原表位的CEA，具有较高的亲和力和特异性。用链霉亲和素（SA）修饰的金纳米颗粒（GNP）用于通过生物素-链霉亲和素相互作用进一步特异性增强信号。链霉亲和素修饰的金纳米颗粒（SA-GNP）对配体生物素的结合能力通过用生物素（5-荧光素）缀合物滴定定量为10.54个生物素结合位点/100 nm（2）。所研制的GNP增强夹心式SPR生物传感器成功地实现了CEA在1-60 ng/mL范围内的灵敏检测，检测限为1.0 ng/mL。与直接测定形式相比，不含GNP的夹心形式和SA-GNP增强的夹心形式的灵敏度分别为4.2倍和13.8倍。该传感器在干扰研究中对CEA也显示出良好的选择性。结果表明，该方法可以提供一个高灵敏度和选择性的检测CEA，并提供了一个有前途的替代癌症生物标志物比传统的临床检查。(C)2015 Elsevier B. V.版权所有。
A new method for real-time detection of carcinoembryonic antigen (CEA) in human serum with high sensitivity and selectivity using surface plasmon resonance (SPR) biosensor was developed. Two kinds of antibodies were used to recognize CEA at different epitopes with high affinity and specificity. Gold nanoparticles (GNPs) modified with streptavidin (SA) were used to further enhance signal specifically via biotin-streptavidin interaction. The binding capacity of the streptavidin-modified gold nanoparticles (SA-GNPs) for ligand biotin was quantified by titration with biotin (5-fluorescein) conjugate to be 10.54 biotin binding sites per 100 nm(2). The developed GNPs enhanced sandwich SPR biosensor successfully fulfilled the sensitive detection of CEA in the range of 1-60 ng/mL with a detection limit of 1.0 ng/mL. Compared to the direct assay format, sandwich format without GNPs and SA-GNPs enhanced sandwich format led to 4.2-fold and 13.8-fold in the sensitivity, respectively. This sensor also showed good selectivity for CEA in the interference study. The results demonstrated that the proposed method could provide a high sensitivity and selectivity in the detection of CEA and offer a promising alternative for cancer biomarker than traditional clinical examinations. (C) 2015 Elsevier B.V. All rights reserved.